Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature

Drug Metab Pers Ther. 2018 Jun 27;33(2):105-108. doi: 10.1515/dmpt-2018-0002.

Abstract

Background: Relapsing polychondritis (RP) is a rare autoimmune disorder, and myelodysplastic syndrome (MDS) is accompanied by RP at variable rates. Herein, we report a case with RP and MDS who responded dramatically to 5-azacitidine for MDS.

Case presentation: With conventional immunosuppressive treatment, our patient had several episodes of different side effects, including infections. With the diagnosis of MDS and initiation of azacitidine treatment, all the manifestations of RP disappeared, and remission was achieved for MDS. Although he had relapses of either RP or MDS after several years of azacitidine treatment, all relapses were controlled well with the initiation of azacitidine treatment every time.

Conclusions: Azacitidine should be kept in mind as a treatment option for RP patients with MDS.

Keywords: azacitidine; myelodysplastic syndrome; relapsing polychondritis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Azacitidine / therapeutic use*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Myelodysplastic Syndromes / diagnosis
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / immunology
  • Polychondritis, Relapsing / diagnosis
  • Polychondritis, Relapsing / drug therapy*
  • Polychondritis, Relapsing / immunology
  • Remission Induction
  • Time Factors
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Azacitidine